Vistide
Withdrawn
This medicine's authorisation has been withdrawn
cidofovir
MedicineHumanWithdrawn
- Application under evaluation
- CHMP opinion
- European Commission decision
Overview
On 22 August 2014, the European Commission withdrew the marketing authorisation for Vistide (cidofovir) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Gilead Sciences International Ltd, which notified the European Commission of its decision to permanently discontinue the marketing of the product.
Vistide was granted marketing authorisation in the EU on 23 April 1997 for the treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS). The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2007. Due to manufacturing problems the product had been in short supply in the EU since February 2013. During the shortage, healthcare professionals used alternative medicinal products and generic medicine containing cidofovir. Due to ongoing manufacturing challenges as well as a decreasing incidence of CMV retinitis in adults with AIDS, Gilead Sciences International Ltd decided to request the withdrawal of the marketing authorisation for Vistide.
The European Public Assessment Report (EPAR) for Vistide is updated accordingly to reflect the fact that the marketing authorisation is no longer valid.
Product information
Latest procedure affecting product information:
N/0034
22/08/2014
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Product details
- Name of medicine
- Vistide
- Active substance
- cidofovir
- International non-proprietary name (INN) or common name
- cidofovir
- Therapeutic area (MeSH)
- Cytomegalovirus Retinitis
- Anatomical therapeutic chemical (ATC) code
- J05AB12
Pharmacotherapeutic group
Antivirals for systemic useTherapeutic indication
Vistide is indicated for the treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome (AIDS) and without renal dysfunction. Vistide should be used only when other agents are considered unsuitable.
News on Vistide
This page was last updated on